COLUMN

What Is the Best Path to Customers’ Hearts and Minds?

June 19, 2017
Philip Carrigan There are over 60,000 medical representatives (MRs) in Japan’s pharmaceutical industry. They make over 90 million visits to doctors per year to provide details of products to those with the authority to prescribe them. Through detailing, doctors learn…

To read the full story

COLUMN

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…